| 1913 | Mochida established by Ryokichi Mochida,and started production and marketing of Luestin (antiluetic) and Ogoko (ophthalmic ointment) |
|---|---|
 |
|
| 1918 | Renamed as Mochida Pharmaceutical Company |
| 1930 | Pelanin (first estrogen preparation developed in Japan) |
| 1945 | Company incorporated |
| 1951 | Released Sprase (first hyaluronidase preparation developed in Japan) |
| 1954 | Began overseas marketing with exports to Taiwan |
| 1956 | Thrombin Mochida (hemostatic enzyme) |
| 1957 | Built a research laboratory at Oji Plant |
| 1959 | Transferred focus of sales strategy to obstetrics and gynecology |
| 1962 | Established the Immunology Division |
| 1963 | Listed on the Second Section of the Tokyo Stock Exchange (TSE) |
| 1964 | Nobuo Mochida appointed president |
| Gonavis (Japan's first immunological pregnancy test kit); Kimotab (anti-inflammatory) | |
 |
|
| 1967 | Completed Research Laboratory in Oji |
| 1970 | Established the Paramedical Division |
| Gonavislide (pregnancy test kit); Uronase (fibrinolytic); Skina Babe (baby bath oil) | |
| 1972 | Established the Medical Electronics and Equipment Division |
| Completed the Shizuoka Plant | |
| 1975 | Listed on the First Section of the TSE |
| 1976 | Completed new headquarters office building at Yotsuya |
| 1978 | Received a Noteworthy Invention Testimonial from the Science and Technology Agency for the Medilaser balance-type surgical laser head |
| 1979 | Rocornal |
| 1980 | Developed monoclonal antibody technology for an immunodiagnostic test Medilaser-S |
| 1981 | Signed an agreement with Hayashibara Biochemical Laboratory,Inc., for joint research of interferon α |
| 1982 | Completed the Fuji Central Research Laboratory |
| 1983 | Established the Mochida Memorial Foundation for Medical and Pharmaceutical Research |
| 1984 | Nobuo Mochida awarded the Medal with Purple Ribbon for research on the first surgical laser unit developed in Japan |
| Arasena-A | |
| 1985 | Ei Mochida appointed president |
| Miraclid | |
 |
|
| 1986 | Florid®-F injection; Grandaxin |
| 1987 | Ei Mochida awarded the Medal with Purple Ribbon for R&D activities on an immunochemical diagnostic reagent |
| 1988 | Signed an agreement with Taisho Pharmaceutical Co.,Ltd., allowing that company to market Dermarin, an OTC drug for treating dermatomycosis |
| Collage Soap series; Isoprinosine; IFN α Mochida 500; IFN β Mochida; Diode-laser therapy unit | |
| 1989 | Finalized agreements with Upjohn Co., for developing and marketing their prostaglandin derivative; with Dojindo Laboratories to develop diagnostic reagents based on FIA |
| Tecipul | |
| 1990 | Susumu Watanabe appointed president |
| Concluded marketing agreement with Matsushita Electric Industrial Co.,Ltd., for the Medilaser-10S fiber-optic carbon dioxide surgical laser unit | |
| Epadel Capsule 300; | |
 |
|
| 1991 | Commenced operations at the Otawara Plant |
| Concluded agreement of an antimycotic agent with Imperial Chemical Industries,PLC | |
| Mammotec | |
| 1992 | Signed agreements with Ostex International,Inc., for the commercialization and marketing of Osteomark®; with Yokogawa-Hewlett-Packard,Ltd., to market an obstetric care unit |
| Medilaser-30S; Arasena-A Ointment; Thrombin Oral Fine Granules; Bathquina | |
| Commenced J-MIC (EBM study for Rocornal) | |
| 1993 | Florid® Oral Gel; Sonotec-IV; Collage Liquid Soap |
| 1994 | Additional indication for Epadel(for hyperlipidemia) approved; Miraclid liquid formulation for injection; Sonovista-EX; Medilaser Soft150 |
| 1995 | Signed agreements with Smithkline Beecham Seiyaku K.K. for the co-marketing of Arasena-A |
| Hismanal®; Fetal Monitors and the Telemetry System; Sonovista-Color; Sonovista-ET | |
| 1996 | Signed agreements with Norian Corporation for the development and marketing in Japan of Norian SRS®; and with Dainippon Pharmaceutical Co.,Ltd., for the co-marketing of Epadel in Japan |
| Commenced JELIS (EBM study for Epadel) | |
| 1997 | Concluded distribution agreement with Ajinomoto Co.,Inc., for Atelec® (calcium channel antagonist) |
| Atelec®; Bilmeter-E; DXA-70; Gonastick; Superthermo | |
| 1998 | Comarketed Dainippon Pharmaceutical's Cetapril® (ACE inhibitor) |
| Osteomark® ; Amtec; Sonovista-Color II; Medilaser Soft 1000 | |
| 1999 | Naoyuki Mochida appointed president |
| Additional indications for IFN α (for CML) and IFN β (for SSPE) approved; concluded distribution agreement with Janssen Kyowa Co.,Ltd., for Ortho® 777-28/M-21; licenesed a patent of Fas/FasL (for genetherapy) to Novartis | |
| Licensed a patent Fas/FasL (for screening) to Bristol Myers Squibb | |
| Epadel S 300 and 600; Video Hysteroscope; Hysterofiberscope; Collage Furfur; Miotecter® | |
 |
|
| 2000 | Signed agreements with Riken for co-research in structual genomics |
| TV probe III; Skina Babe Series (renewal); AuDX | |
| 2001 | Signed agreements with 3M for the development and marketing of Aldara; with Maruishi Pharmaceutical Co.,Ltd. for the co-development and co-marketing of capsaicin |
| Arasena-A 3% cream; Gonastick 25; Collage Essence | |
| 2002 | Signed agreements with Aventis Pharma Ltd. for the distribution and co-promotion of Suprecur®; with Lundbeck A/S for the co-development and co-marketing of escitalopram Established Neutrapharmaceutical business |
| Spurecur®; Medilaser-RF; Sonovista-ColorFD | |
| Obtained the certification of ISO 14001 for Otawara Plant | |
| 2003 | Signed agreements with Novo Nordisk for the distribution of Novo-Heparin; with Medix Biochemica Oy and Unitika Ltd. for the distribution of a diagnostic test kit for acute pancreatitis |
| Started operation of Mochida Medical Systems Co.,Ltd. | |
| Thrombin Mochida Soft bottle; FM2; ABaer Cub; Collage S series; and a masticatory supplement |
|
| 2004 | Started operation of Mochida Healthcare Co.,Ltd. |
| Started operation of Mochida Siemens Medical Systems Co.,Ltd. | |
| Epadel S 900; Sonovista-C3000 | |
| 2005 | Started operation of Mochida Pharmaceutical Plant Co.,Ltd. |
| Sonovista G40; Sonovista G60 S; Collage Furfur Liquid Soap; Collage Furfur S | |
| 2006 | Sonovista G60 S; Medilaser Soft Pulse 10; Sonovista X500; Sonovista X300; Acuson X300 |
| 2007 | Signed agreements with JCR Pharmaceuticals Co., Ltd. for co-development and commercialization of a stem cell drug; with Novartis Pharma K.K. for the co-promotion of Diovan® (agreement terminated end of 2008); and with United Therapeutics Corporation for the distribution of Remodulin®. |
| Beselna Cream 5% | |
 |
|
| 2008 | Signed a license agreement with Wyeth Pharmaceuticals for TRPV1 receptor antagonists (agreement terminated 2010). |
| Dinagest; Divigel®; Collage White Peel | |
| 2009 | Signed a license agreement with Shire Pharmaceuticals Group plc (U.K.) for LIALDA®. |
| Gonastick W; Collage Furfur Next | |
| 2010 | Signed agreement with Fuji Pharma Co., Ltd. for co-development of G-CSF; and with Mitsubishi Tanabe Pharma Corporation for co-marketing of escitalopram. |
| 2011 | Signed a license agreement with Merck (MSD outside the United States and Canada) for the potential treatment for type-2 diabetes (agreement terminated 2015). |
| Lexapro® | |
| 2012 | Fastic® |
 |
|
| 2013 | Collage B.K.AGE; Filgastim BS MOCHIDA; Tramcet® |
| 2014 | Atedio®; Collage; Treprost® |
 |
|
| 2015 | Collage Furfur Soap[pink] |
| 2016 | Collage Furfur Hair Growth spray; Lialda® |
 |
|
| 2017 | Calprotectin MOCHIDA; Dienogest Tab/OD Tab MOCHIDA |
 |
|
| 2018 | Doxil®; Goofice®; Etanercept BS「MA」; Collage Furfur Premium Shampoo; Movicol® |
 |
|
| 2019 | Collage Repair series; Teriparatide BS「MOCHIDA」 |
 |
|
| 2020 | Gonacard W; Urece®; Dinagest |
 |
|
| 2021 | Calprotectin POCT MOCHIDA; Collage Furfur Hair Growth Foam; Adalimumab BS「MA」 |
 |
|
| 2022 | Collage Furfur Scalp Shampoo; Movicol®HD; Epadel EM |
 |
|
